Osteoporosis

>

Latest News

FDA Approves Denosumab-bddz for Osteoporosis, Cancer-Related Skeletal Events
FDA Approves Denosumab-bddz for Osteoporosis, Cancer-Related Skeletal Events

March 5th 2024

The decision was based on clinical studies demonstrating no clinically meaningful differences between the biosimilar and its reference product.

US FDA logo in black over a white background. | Credit: US Food and Drug Administration
FDA Adds Boxed Warning to Denosumab (Prolia) for Severe Hypocalcemia

January 19th 2024

DPP-4i Treatment Significantly Reduces Osteoporosis Risk in Patients with Type 2 Diabetes
DPP-4i Treatment Significantly Reduces Osteoporosis Risk in Patients with Type 2 Diabetes

December 19th 2023

Advancing Personalized Web-Based Decision Reports for Enhanced Patient Care
Advancing Personalized Web-Based Decision Reports for Enhanced Patient Care

July 9th 2023

Miriam Bredella, MD | Credit: Harvard Medical School
Study Links Weight Loss Surgery in Adolescents, Young Adults to Weakened Bones

June 13th 2023

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.